BiotechTube

Nifurtimox + Cyclophosphamide + Topotecan

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuroblastoma

Conditions

Neuroblastoma, Medulloblastoma

Trial Timeline

Jan 14, 2008 → Oct 28, 2022

NCT ID
NCT00601003

About Nifurtimox + Cyclophosphamide + Topotecan

Nifurtimox + Cyclophosphamide + Topotecan is a phase 2 stage product being developed by Bayer for Neuroblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00601003. Target conditions include Neuroblastoma, Medulloblastoma.

What happened to similar drugs?

0 of 1 similar drugs in Neuroblastoma were approved

Approved (0) Terminated (0) Active (1)
🔄18F-MFBGIlluminaPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00601003Phase 2Completed

Competing Products

20 competing products in Neuroblastoma

See all competitors
ProductCompanyStageHype Score
LY3295668 Erbumine + Topotecan + CyclophosphamideEli LillyPhase 1
33
ZD6474 + Retinoic AcidAstraZenecaPhase 1
21
Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acidAstraZenecaPhase 2
35
PRRT with 177Lu-DOTATATENovartisPhase 1
36
Topotecan + Temozolomide + RibociclibNovartisPhase 1
21
Topotecan hydrochlorideNovartisPhase 2
35
Ribociclib + CeritinibNovartisPhase 1
21
Bevacizumab + Temozolomide + Temozolomide + Irinotecan + Bevacizumab + Topotecan + Temozolomide + Dinutuximab Beta + CyclophosphamideRochePhase 2
39
GPC2 CAR T cellsGilead SciencesPhase 1
36
lorlatinibPfizerPre-clinical
18
Lorlatinib + Cyclophosphamide + Topotecan + Filgrastim/pegfilgrastimPfizerPhase 1
29
DinutuximabUnited TherapeuticsPre-clinical
15
Dinutuximab with ChemotherapyUnited TherapeuticsPhase 1
30
ch14.18 -NCI + ch14.18-UTC + Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) + Aldesleukin (IL-2) + IsotretinoinUnited TherapeuticsPhase 1/2
29
Dinutuximab + Irinotecan Hydrochloride + Sargramostim + Temozolomide + TemsirolimusUnited TherapeuticsPhase 2
32
Dinutuximab + NK Cells + LenalidomideUnited TherapeuticsPhase 1
30
MAb-3F8 + Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) + 13-cis-Retinoic AcidUnited TherapeuticsPhase 2
24
Radiation: 131I-MIBG + Dinutuximab + VorinostatUnited TherapeuticsPhase 2
39
Dinutuximab + Vorinostat + Sargramostim + Potassium IodideUnited TherapeuticsPhase 1
26
Universal Donor (UD) TGFβi NK Cells + Temozolomide + Irinotecan + Dinutuximab + GM-CSFUnited TherapeuticsPhase 2
39